Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?

Lucchini E, Zaja F, Bussel J.

Haematologica. 2019 Jun;104(6):1124-1135. doi: 10.3324/haematol.2019.218883. Epub 2019 May 24. Review.

2.

KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival.

Vendramini E, Bomben R, Pozzo F, Benedetti D, Bittolo T, Rossi FM, Dal Bo M, Rabe KG, Pozzato G, Zaja F, Chiarenza A, Di Raimondo F, Braggio E, Parikh SA, Kay NE, Shanafelt TD, Del Poeta G, Gattei V, Zucchetto A.

Leukemia. 2019 Mar 14. doi: 10.1038/s41375-019-0444-6. [Epub ahead of print] No abstract available.

PMID:
30872781
3.

Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma.

Maura F, Agnelli L, Leongamornlert D, Bolli N, Chan WC, Dodero A, Carniti C, Heavican TB, Pellegrinelli A, Pruneri G, Butler A, Bhosle SG, Chiappella A, Di Rocco A, Zinzani PL, Zaja F, Piva R, Inghirami G, Wang W, Palomero T, Iqbal J, Neri A, Campbell PJ, Corradini P.

Am J Hematol. 2019 Jun;94(6):628-634. doi: 10.1002/ajh.25450. Epub 2019 Mar 19.

PMID:
30829413
4.

A B-cell receptor-related gene signature predicts response to ibrutinib treatmeant in mantle cell lymphoma cell lines.

D'Agaro T, Zucchetto A, Vit F, Bittolo T, Tissino E, Rossi FM, Degan M, Zaja F, Bulian P, Dal Bo M, Ferrero S, Ladetto M, Zamò A, Gattei V, Bomben R.

Haematologica. 2019 Feb 28. pii: haematol.2018.212811. doi: 10.3324/haematol.2018.212811. [Epub ahead of print]

5.

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.

Klanova M, Sehn LH, Bence-Bruckler I, Cavallo F, Jin J, Martelli M, Stewart D, Vitolo U, Zaja F, Zhang Q, Mattiello F, Sellam G, Punnoose EA, Szafer-Glusman E, Bolen CR, Oestergaard MZ, Fingerle-Rowson GR, Nielsen T, Trneny M.

Blood. 2019 Feb 28;133(9):919-926. doi: 10.1182/blood-2018-07-862862. Epub 2019 Jan 7.

6.

Management of immune thrombocytopenia in elderly patients.

Lucchini E, Fanin R, Cooper N, Zaja F.

Eur J Intern Med. 2018 Dec;58:70-76. doi: 10.1016/j.ejim.2018.09.005. Epub 2018 Sep 29. Review.

PMID:
30274902
7.

Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.

Tedeschi A, Conticello C, Rizzi R, Benevolo G, Laurenti L, Petrucci MT, Zaja F, Varettoni M.

Hematol Oncol. 2019 Apr;37(2):117-128. doi: 10.1002/hon.2539. Epub 2018 Sep 7. Review.

PMID:
30192023
8.

High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.

Avivi I, Arcaini L, Ferretti VV, Boumendil A, Finel H, Milone G, Zaja F, Liliana D, Musso M, Didier B, Bachy E, Wattad M, Nicolas-Virelizier E, Gramatzki M, Bourhis JH, Caillot D, Haenel A, Held G, Thieblemont C, Jindra P, Pohlreich D, Guilhot F, Kroschinsky F, Wahlin B, Scheid C, Ifrah N, Berthou C, Dreger P, Montoto S, Conconi A.

Br J Haematol. 2018 Sep;182(6):807-815. doi: 10.1111/bjh.15454. Epub 2018 Jul 9.

PMID:
29984825
9.

MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.

Ambrosio MR, Lazzi S, Bello GL, Santi R, Porro LD, de Santi MM, Guazzo R, Mundo L, Rigacci L, Kovalchuck S, Onyango N, Fabbri A, Cencini E, Zinzani PL, Zaja F, Angrilli F, Stelitano C, Cabras MG, Spataro G, Bob R, Menter T, Granai M, Cevenini G, Naresh KN, Stein H, Sabattini E, Leoncini L.

Haematologica. 2019 Jan;104(1):e25-e28. doi: 10.3324/haematol.2018.195958. Epub 2018 Jun 28. No abstract available.

10.

Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study.

Rossi G, Gramegna D, Paoloni F, Fattizzo B, Binda F, D'Adda M, Farina M, Lucchini E, Mauro FR, Salvi F, Marchetti M, Fazi P, Zaja F, Barcellini W.

Blood. 2018 Aug 2;132(5):547-550. doi: 10.1182/blood-2018-03-835413. Epub 2018 Jun 13. No abstract available.

PMID:
29898955
11.

A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.

Olivieri J, Mosna F, Pelosini M, Fama A, Rattotti S, Giannoccaro M, Carli G, Tisi MC, Ferrero S, Sgherza N, Mazzone AM, Marino D, Calimeri T, Loseto G, Saraceni F, Tomei G, Sica S, Perali G, Codeluppi K, Billio A, Olivieri A, Orciuolo E, Matera R, Stefani PM, Borghero C, Ghione P, Cascavilla N, Lanza F, Chiusolo P, Finotto S, Federici I, Gherlinzoni F, Centurioni R, Fanin R, Zaja F; Fondazione Italiana Linfomi Postgraduate Master Course.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1814-1822. doi: 10.1016/j.bbmt.2018.05.018. Epub 2018 May 29.

PMID:
29857196
12.

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.

Bussel J, Arnold DM, Grossbard E, Mayer J, Treliński J, Homenda W, Hellmann A, Windyga J, Sivcheva L, Khalafallah AA, Zaja F, Cooper N, Markovtsov V, Zayed H, Duliege AM.

Am J Hematol. 2018 Jul;93(7):921-930. doi: 10.1002/ajh.25125. Epub 2018 May 15.

13.

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.

Zaja F, Salvi F, Rossi M, Sabattini E, Evangelista A, Ciccone G, Angelucci E, Gaidano G, Zanni M, Ladetto M, Chiappella A, Vitolo U, Zinzani PL, Califano C, Tucci A, Patti C, Pileri SA, Lenti V, Piccaluga PP, Cavallo F, Volpetti S, Perali G, Assouline S, Mann KK, Morin R, Alcaide M, Bushell K, Fanin R, Levis A.

Leuk Lymphoma. 2018 Dec;59(12):2904-2910. doi: 10.1080/10428194.2018.1452208. Epub 2018 Apr 4.

PMID:
29616865
14.

Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.

Collins GP, Rueda A, Salles G, von Tresckow B, Zaja F.

Leuk Lymphoma. 2018 Sep;59(9):2113-2120. doi: 10.1080/10428194.2017.1421762. Epub 2018 Jan 16.

PMID:
29334819
15.

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.

Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A.

J Exp Med. 2018 Feb 5;215(2):681-697. doi: 10.1084/jem.20171288. Epub 2018 Jan 4.

16.

Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.

Dreyling M, Aurer I, Cortelazzo S, Hermine O, Hess G, Jerkeman M, Le Gouill S, Ribrag V, Trněný M, Visco C, Walewski J, Zaja F, Zinzani PL.

Leuk Lymphoma. 2018 Aug;59(8):1814-1828. doi: 10.1080/10428194.2017.1403602. Epub 2017 Nov 27. Review.

PMID:
29172868
17.

Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers.

Cantoni S, Carpenedo M, Mazzucconi MG, De Stefano V, Carrai V, Ruggeri M, Specchia G, Vianelli N, Pane F, Consoli U, Artoni A, Zaja F, D'adda M, Visentin A, Ferrara F, Barcellini W, Caramazza D, Baldacci E, Rossi E, Ricco A, Ciminello A, Rodeghiero F, Nichelatti M, Cairoli R.

Am J Hematol. 2018 Jan;93(1):58-64. doi: 10.1002/ajh.24935. Epub 2017 Nov 9.

18.

NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.

Benedetti D, Tissino E, Pozzo F, Bittolo T, Caldana C, Perini C, Martorelli D, Bravin V, D'Agaro T, Rossi FM, Bomben R, Santinelli E, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Poeta G, Rossi D, Gaidano G, Dal Bo M, Gattei V, Zucchetto A.

Leukemia. 2018 Mar;32(3):654-662. doi: 10.1038/leu.2017.296. Epub 2017 Sep 22.

PMID:
28935990
19.

Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review.

Righi E, Carnelutti A, Muser D, Zaja F, Lucchini E, Pea F, Di Gregorio F, Alavi A, Bassetti M.

J Neurovirol. 2017 Dec;23(6):908-912. doi: 10.1007/s13365-017-0566-4. Epub 2017 Aug 18.

PMID:
28822107
20.

Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia.

Bulian P, Bomben R, Bo MD, Zucchetto A, Rossi FM, Degan M, Pozzo F, Bittolo T, Bravin V, D'Agaro T, Cerri M, Chiarenza A, Chaffee KG, Condoluci A, D'Arena G, Spina M, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Poeta GD, Gaidano G, Shanafelt TD, Gattei V.

Haematologica. 2017 Nov;102(11):e443-e446. doi: 10.3324/haematol.2017.170340. Epub 2017 Jul 27. No abstract available.

21.

NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.

D'Agaro T, Bittolo T, Bravin V, Dal Bo M, Pozzo F, Bulian P, Rossi FM, Zucchetto A, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Bomben R.

Br J Haematol. 2018 Aug;182(4):597-602. doi: 10.1111/bjh.14843. Epub 2017 Jul 12. No abstract available.

PMID:
28699643
22.

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.

Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U.

Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.

PMID:
28668386
23.

Mutations in the 3' untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia.

Bittolo T, Pozzo F, Bomben R, D'Agaro T, Bravin V, Bulian P, Rossi FM, Zucchetto A, Degan M, Macor P, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M.

Haematologica. 2017 Aug;102(8):e305-e309. doi: 10.3324/haematol.2016.162594. Epub 2017 May 26. No abstract available.

24.

Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi.

Luminari S, Viel E, Ferreri AJM, Zaja F, Chimienti E, Musuraca G, Tucci A, Balzarotti M, Tani M, Salvi F, Pesce EA, Ferrari A, Liberati AM, Spadea A, Marino D, Bruno-Ventre M, Volpetti S, Bottelli C, Ravaioli E, Merli F, Spina M.

Hematol Oncol. 2018 Feb;36(1):68-75. doi: 10.1002/hon.2425. Epub 2017 May 19.

PMID:
28524259
25.

New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?

Patriarca F, Giaccone L, Onida F, Castagna L, Sarina B, Montefusco V, Mussetti A, Mordini N, Maino E, Greco R, Peccatori J, Festuccia M, Zaja F, Volpetti S, Risitano A, Bassan R, Corradini P, Ciceri F, Fanin R, Baccarani M, Rambaldi A, Bonifazi F, Bruno B.

Expert Opin Biol Ther. 2017 Jul;17(7):821-836. doi: 10.1080/14712598.2017.1324567. Epub 2017 May 22. Review.

PMID:
28506131
26.

Role of bone marrow biopsy in staging of patients with classical Hodgkin's lymphoma undergoing positron emission tomography/computed tomography.

Puccini B, Nassi L, Minoia C, Volpetti S, Ciancia R, Riccomagno PC, Di Rocco A, Mulè A, Toldo C, Sassone MC, Guariglia R, Filì C, Finolezzi E, Falorio S, Zanon S, Furlan A, Doa G, Zaja F; Fondazione Italiana Linfomi Postgraduate Master course.

Ann Hematol. 2017 Jul;96(7):1147-1153. doi: 10.1007/s00277-017-2996-8. Epub 2017 Apr 28.

PMID:
28451805
27.

NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.

Pozzo F, Bittolo T, Vendramini E, Bomben R, Bulian P, Rossi FM, Zucchetto A, Tissino E, Degan M, D'Arena G, Di Raimondo F, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M.

Leukemia. 2017 Nov;31(11):2407-2415. doi: 10.1038/leu.2017.90. Epub 2017 Mar 21.

PMID:
28321119
28.

Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.

Ferreri AJ, Sassone M, Zaja F, Re A, Spina M, Rocco AD, Fabbri A, Stelitano C, Frezzato M, Rusconi C, Zambello R, Couto S, Ren Y, Arcari A, Bertoldero G, Nonis A, Scarfò L, Calimeri T, Cecchetti C, Chiozzotto M, Govi S, Ponzoni M.

Lancet Haematol. 2017 Mar;4(3):e137-e146. doi: 10.1016/S2352-3026(17)30016-9. Epub 2017 Feb 17.

PMID:
28219694
29.

Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.

Zaja F, Ferrero S, Stelitano C, Ferrari A, Salvi F, Arcari A, Musuraca G, Botto B, Spina M, Cellini C, Patti C, Liberati AM, Minotto C, Pileri SA, Ceccarelli M, Volpetti S, Ferranti A, Drandi D, Montechiarello E, Ladetto M, Carmichael J, Fanin R.

Haematologica. 2017 May;102(5):e203-e206. doi: 10.3324/haematol.2016.154211. Epub 2017 Jan 12. No abstract available.

30.

Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response.

Marangon M, Vianelli N, Palandri F, Mazzucconi MG, Santoro C, Barcellini W, Fattizzo B, Volpetti S, Lucchini E, Polverelli N, Carpenedo M, Isola M, Fanin R, Zaja F.

Eur J Haematol. 2017 Apr;98(4):371-377. doi: 10.1111/ejh.12839. Epub 2017 Jan 20.

PMID:
27981682
31.

Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.

Mauro FR, Carella AM, Molica S, Paoloni F, Liberati AM, Zaja F, Belsito V, Cortellezzi A, Rizzi R, Tosi P, Spriano M, Ferretti A, Nanni M, Marinelli M, De Propris MS, Orlando SM, Vignetti M, Cuneo A, Guarini AR, Foà R.

Leuk Lymphoma. 2017 Jul;58(7):1640-1647. doi: 10.1080/10428194.2016.1258698. Epub 2016 Nov 23.

PMID:
27881039
32.

CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?

Zaja F, Tabanelli V, Agostinelli C, Calleri A, Chiappella A, Varettoni M, Luigi Zinzani P, Volpetti S, Sabattini E, Fanin R, Pileri SA.

Am J Hematol. 2017 Jan;92(1):E1-E2. doi: 10.1002/ajh.24571. Epub 2016 Nov 10. No abstract available.

33.

Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.

Arcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M, Visentini M, Torres HA, Loustaud-Ratti V, Peveling-Oberhag J, Fabris P, Rossotti R, Zaja F, Rigacci L, Rattotti S, Bruno R, Merli M, Dorival C, Alric L, Jaccard A, Pol S, Carrat F, Ferretti VV, Visco C, Hermine O.

Blood. 2016 Nov 24;128(21):2527-2532. Epub 2016 Sep 7.

34.

Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia.

Boggio E, Gigliotti CL, Rossi D, Toffoletti E, Cappellano G, Clemente N, Puglisi S, Lunghi M, Cerri M, Vianelli N, Cantoni S, Tieghi A, Beggiato E, Gaidano G, Comi C, Chiocchetti A, Fanin R, Dianzani U, Zaja F.

Br J Haematol. 2017 Jan;176(2):258-267. doi: 10.1111/bjh.14248. Epub 2016 Jul 8.

PMID:
27391055
35.

The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study.

Zinzani PL, Rigacci L, Cox MC, Devizzi L, Fabbri A, Zaja F, Di Rocco A, Rossi G, Storti S, Fattori PP, Argnani L, Vitolo U.

Leuk Lymphoma. 2017 Jan;58(1):226-229. Epub 2016 Jun 2. No abstract available.

PMID:
27252040
36.

CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.

Dal Bo M, Bulian P, Bomben R, Zucchetto A, Rossi FM, Pozzo F, Tissino E, Benedetti D, Bittolo T, Nanni P, Cattarossi I, Zaina E, Chivilò H, Degan M, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Principe MI, Del Poeta G, Rossi D, Gaidano G, Gattei V.

Leukemia. 2016 Oct;30(10):2011-2018. doi: 10.1038/leu.2016.88. Epub 2016 Apr 25.

PMID:
27109509
37.

Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.

Mondello P, Steiner N, Willenbacher W, Wasle I, Zaja F, Zambello R, Visentin A, Mauro E, Ferrero S, Ghione P, Pitini V, Cuzzocrea S, Mian M.

Ann Hematol. 2016 Jun;95(7):1107-14. doi: 10.1007/s00277-016-2668-0. Epub 2016 Apr 22.

PMID:
27103007
38.

Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.

Zaja F, Barcellini W, Cantoni S, Carpenedo M, Caparrotti G, Carrai V, Di Renzo N, Santoro C, Di Nicola M, Veneri D, Simonetti F, Liberati AM, Ferla V, Paoloni F, Crea E, Volpetti S, Tuniz E, Fanin R.

Am J Hematol. 2016 May;91(5):E293-5. doi: 10.1002/ajh.24341. Epub 2016 Apr 4.

39.

Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.

Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A.

J Clin Oncol. 2016 Apr 20;34(12):1376-85. doi: 10.1200/JCO.2015.63.0699. Epub 2016 Feb 16.

40.

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, Varettoni M, Altman JK, Anastasia A, Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Foà R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B, Tallman MS.

N Engl J Med. 2015 Oct 29;373(18):1733-47. doi: 10.1056/NEJMoa1506583. Epub 2015 Sep 9.

41.

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.

Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G.

Blood. 2015 Oct 15;126(16):1921-4. doi: 10.1182/blood-2015-05-647925. Epub 2015 Aug 14.

42.

Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?

Benedetti D, Tissino E, Caldana C, Dal Bo M, Bomben R, Marconi D, Ganghammer S, Zaja F, Pozzato G, Di Raimondo F, Hartmann TN, Del Poeta G, VanMeter A, Zucchetto A, Espina V, Liotta L, Gattei V.

Leukemia. 2016 Feb;30(2):513-7. doi: 10.1038/leu.2015.149. Epub 2015 Jun 19. No abstract available.

PMID:
26183532
43.

NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.

Pozzo F, Bittolo T, Arruga F, Bulian P, Macor P, Tissino E, Gizdic B, Rossi FM, Bomben R, Zucchetto A, Benedetti D, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Deaglio S, Gattei V, Dal Bo M.

Leukemia. 2016 Jan;30(1):182-9. doi: 10.1038/leu.2015.182. Epub 2015 Jul 13.

PMID:
26165233
44.

The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.

Dal Bo M, D'Agaro T, Gobessi S, Zucchetto A, Dereani S, Rossi D, Zaja F, Pozzato G, Di Raimondo F, Gaidano G, Laurenti L, Del Poeta G, Efremov DG, Gattei V, Bomben R.

Oncotarget. 2015 Aug 7;6(22):19102-17.

45.

Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.

Tedeschi A, Picardi P, Ferrero S, Benevolo G, Margiotta Casaluci G, Varettoni M, Baratè C, Motta M, Gini G, Goldaniga MC, Visco C, Zaja F, Belsito Petrizi V, Ravelli E, Gentile M, Urbano MA, Franceschetti S, Ghione P, Orsucci L, Frustaci AM, Gaidano G, Vitolo U, Morra E.

Leuk Lymphoma. 2015;56(9):2637-42. doi: 10.3109/10428194.2015.1012714. Epub 2015 Mar 14.

PMID:
25651423
46.

Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma.

Dozzo M, Zaja F, Volpetti S, Sperotto A, Magli A, Fanin R.

Am J Hematol. 2015 Apr;90(4):E73. doi: 10.1002/ajh.23925. Epub 2015 Mar 9. No abstract available.

47.

A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma.

Mian M, Marcheselli L, Rossi A, Visco C, Chiappella A, Volpetti S, Zaja F, Mondello P, Fiegl M, Billio A, Federico M, Luminari S, Rambaldi A, Cortelazzo S.

Ann Oncol. 2014 Dec;25(12):2398-404. doi: 10.1093/annonc/mdu462. Epub 2014 Oct 1.

PMID:
25274614
48.

Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.

Zinzani PL, Rigacci L, Cox MC, Devizzi L, Fabbri A, Zaccaria A, Zaja F, Di Rocco A, Rossi G, Storti S, Fattori PP, Argnani L, Tura S, Vitolo U.

Leuk Lymphoma. 2015 Jun;56(6):1671-6. doi: 10.3109/10428194.2014.964702. Epub 2014 Nov 19.

PMID:
25241999
49.

Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network.

Dreyling M, Amador V, Callanan M, Jerkeman M, Le Gouill S, Pott C, Rule S, Zaja F; European Mantle Cell Lymphoma Network.

Leuk Lymphoma. 2015 Apr;56(4):866-76. doi: 10.3109/10428194.2014.940584. Epub 2014 Aug 20.

PMID:
25015778
50.

Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors.

Ruggeri M, Tosetto A, Palandri F, Polverelli N, Mazzucconi MG, Santoro C, Gaidano G, Lunghi M, Zaja F, De Stefano V, Sartori R, Fazi P, Rodeghiero F; Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Anemia and Thrombocytopenias Working Party. GIMEMA Study ITP0311.

J Thromb Haemost. 2014 Aug;12(8):1266-73. doi: 10.1111/jth.12636. Epub 2014 Jul 16.

Supplemental Content

Support Center